Physician profile
Robin Malik
NPI 1013279215
$8,154.23
in general payments reported to CMS, 2019-2025
46 companies · $1,802 in 2025
The $1,802 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $629 · 2022: $1,529 · 2023: $1,801 · 2024: $2,393 · 2025: $1,802.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,812 · Education: $185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,811.63 |
| Education | $184.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,167.50 | 2021-2025 | |
| Novo Nordisk INC | $881.30 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $724.08 | 2021-2025 | |
| Lilly USA, LLC | $697.85 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $543.02 | 2021-2025 | Repatha, Evenity, Prolia |
| Astellas Pharma US INC | $421.34 | 2022-2025 | Veozah, Myrbetriq |
| Exact Sciences Corporation | $307.10 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $271.52 | 2021-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $250.44 | 2021-2025 | Xifaxan |
| Glaxosmithkline, LLC. | $225.45 | 2021-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Esperion Therapeutics, INC. | $222.24 | 2022-2025 | Nexletol |
| Sumitomo Pharma America, INC. | $190.07 | 2023-2025 | Gemtesa |
| Takeda Pharmaceuticals U.S.A., INC. | $183.33 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $168.76 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $151.90 | 2021-2024 | Eliquis |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $139.04 | 2021-2023 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $118.99 | 2021-2022 | |
| Dynavax Technologies Corporation | $118.03 | 2024 | Heplisav-B |
| Abbott Laboratories | $112.66 | 2022-2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals Lp | $108.34 | 2021-2025 | Breztri, Farxiga |
| Shield Therapeutics INC | $107.49 | 2025 | |
| Idorsia Pharmaceuticals US INC | $92.72 | 2022-2024 | Quviviq |
| Daiichi Sankyo INC. | $87.46 | 2022-2025 | Injectafer |
| Dexcom, INC. | $78.91 | 2023-2024 | Dexcom G6 Transmitter |
| Ardelyx, INC. | $72.17 | 2024 | Ibsrela |
| Corium, LLC | $66.14 | 2023 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $57.18 | 2023-2024 | Rexulti |
| Phathom Pharmaceuticals, INC. | $51.66 | 2024 | Voquezna |
| Cequr Corporation | $50.00 | 2025 | Cequr Simplicity |
| Edwards Lifesciences Corporation | $45.18 | 2022-2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Merck Sharp & Dohme LLC | $41.86 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
| Eisai INC. | $36.92 | 2021-2022 | |
| Alkermes, INC. | $35.66 | 2024 | Vivitrol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $34.62 | 2024 | Caplyta |
| Biohaven Pharmaceuticals, INC. | $32.96 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $31.37 | 2022 | |
| Vivus LLC | $31.24 | 2021 | |
| Harmony Biosciences LLC | $29.47 | 2024 | |
| Scynexis, INC. | $27.57 | 2022 | |
| Ascensia Diabetes Care US INC. | $24.56 | 2025 | |
| Boston Scientific Corporation | $24.50 | 2025 | Ams 700 |
| Intuity Medical INC | $23.65 | 2022 | |
| Medtronic, INC. | $22.58 | 2024 | Intellis Adaptivestim |
| Gilead Sciences, INC. | $18.14 | 2021 | |
| Amarin Pharma, INC. | $14.43 | 2021 | |
| Almatica Pharma LLC | $12.83 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Malik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.